Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Supratentorial glioblastoma treated with radiotherapy: use of the Radiation Therapy Oncology Group recursive partitioning analysis grouping for predicting survival.

Fujii O, Soejima T, Kuwatsuka Y, Harada A, Ota Y, Tsujino K, Sasaki M, Kudo H, Nishihara M, Taomoto K.

Jpn J Clin Oncol. 2010 Aug;40(8):726-31. doi: 10.1093/jjco/hyq051. Epub 2010 Apr 21.

PMID:
20410057
2.

Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution.

Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH.

Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):981-7.

PMID:
9869219
3.

Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors.

Chang EL, Yi W, Allen PK, Levin VA, Sawaya RE, Maor MH.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):519-28.

PMID:
12738329
4.

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9.

PMID:
11516860
5.

Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.

Videtic GM, Gaspar LE, Zamorano L, Stitt LW, Fontanesi J, Levin KJ.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):963-8.

PMID:
11704318
6.

Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.

Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST.

J Neurosurg. 2011 Aug;115(2):220-9. doi: 10.3171/2011.3.JNS10495. Epub 2011 May 6.

PMID:
21548745
7.

Radiotherapy in supratentorial gliomas. A study of 821 cases.

Heesters M, Molenaar W, Go GK.

Strahlenther Onkol. 2003 Sep;179(9):606-14.

PMID:
14628126
8.
9.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
10.

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).

Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, K├Âlbl O, Flentje M.

BMC Cancer. 2006 Oct 18;6:247.

11.

Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas.

Videtic GM, Gaspar LE, Zamorano L, Fontanesi J, Levin KJ, Kupsky WJ, Tekyi-Mensah S.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92.

PMID:
10524423
12.

Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.

Ogawa K, Ishiuchi S, Inoue O, Yoshii Y, Saito A, Watanabe T, Iraha S, Toita T, Kakinohana Y, Ariga T, Kasuya G, Murayama S.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):732-8. doi: 10.1016/j.ijrobp.2010.12.070. Epub 2011 Mar 21.

PMID:
21420247
13.
14.

Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?

Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K.

Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302.

PMID:
10661335
15.

Radiation therapy with uneven fractionation for malignant gliomas.

Nemoto K, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Fujimoto K, Nomiya T, Saito H, Takai Y, Yamada S.

Oncol Rep. 2001 Jan-Feb;8(1):103-6.

PMID:
11115578
16.

Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme.

Mizumoto M, Tsuboi K, Igaki H, Yamamoto T, Takano S, Oshiro Y, Hayashi Y, Hashii H, Kanemoto A, Nakayama H, Sugahara S, Sakurai H, Matsumura A, Tokuuye K.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):98-105. doi: 10.1016/j.ijrobp.2009.04.054. Epub 2009 Aug 19.

PMID:
19695794
17.

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.

J Natl Cancer Inst. 1993 May 5;85(9):704-10.

PMID:
8478956
18.

The role of tumor resection in the treatment of glioblastoma multiforme in adults.

Kreth FW, Berlis A, Spiropoulou V, Faist M, Scheremet R, Rossner R, Volk B, Ostertag CB.

Cancer. 1999 Nov 15;86(10):2117-23.

PMID:
10570440
19.

The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.

Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, Shenouda G, Souhami L.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):247-52.

PMID:
14697445
20.

Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.

Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK; Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):818-24. Epub 2006 Aug 2.

PMID:
16887285

Supplemental Content

Support Center